Patents by Inventor Alvin Y. Liu
Alvin Y. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10725053Abstract: Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.Type: GrantFiled: December 12, 2017Date of Patent: July 28, 2020Assignees: Battelle Memorial Institute, University of WashingtonInventors: Wei-Jun Qian, Tujin Shi, Alvin Y. Liu
-
Publication number: 20180164329Abstract: Methods are provided for treating a subject with prostate cancer and/or diagnosing a subject at risk for prostate cancer, which can include measuring increased expression of at least two prostate cancer-related molecules in a sample obtained from a subject, including the prostate cancer-related molecules AGR2, AGR3, CRISP3, CCL3, CEACAM5, CEACAM6, IL24, MMP9, CXCL14, CD90, POSTN, and SFRP4. The methods can include administering at therapy to a subject with prostate cancer. Methods are provided for treating a subject with intermediate- or high-risk prostate cancer, which can include measuring increased expression of MMP9 in a sample obtained from a subject compared to a control representing expression of MMP9 expected in a sample from a subject who has low-risk prostate cancer.Type: ApplicationFiled: December 12, 2017Publication date: June 14, 2018Inventors: Wei-Jun Qian, Tujin Shi, Alvin Y. Liu
-
Patent number: 6893625Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: GrantFiled: August 1, 2000Date of Patent: May 17, 2005Assignee: Royalty Pharma Finance TrustInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 6652852Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: GrantFiled: November 28, 2000Date of Patent: November 25, 2003Assignee: Royalty Pharma Finance TrustInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Publication number: 20030096343Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.Type: ApplicationFiled: January 9, 2002Publication date: May 22, 2003Applicant: XOMA Technology Ltd.Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 6204023Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts tansformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.Type: GrantFiled: June 6, 1995Date of Patent: March 20, 2001Assignee: XOMA Ltd.Inventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 6120767Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses.Type: GrantFiled: February 12, 1998Date of Patent: September 19, 2000Assignees: Pharmaceutical Royalties, L.L.C., Bioventure Investments, kftInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 5846818Abstract: The invention is directed to the pectate lyase B secretion signal and its use to express operably linked sequences in bacterial hosts.Type: GrantFiled: June 6, 1995Date of Patent: December 8, 1998Assignee: XOMA CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horowitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5721108Abstract: The present invention relates to a chimeric antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a variable region and a human constant region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. The invention is also related to methods of use for such antibody.Type: GrantFiled: June 6, 1995Date of Patent: February 24, 1998Assignee: XOMA CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 5698435Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.Type: GrantFiled: June 6, 1995Date of Patent: December 16, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5698417Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.Type: GrantFiled: June 6, 1995Date of Patent: December 16, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5693493Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains. The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable of binding antigens on target cancer cells.Type: GrantFiled: May 25, 1995Date of Patent: December 2, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5677180Abstract: The present invention relates to a eukaryotic host cell that contains DNA encoding a chimeric antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a variable region and a human constant region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. The invention is also related to methods of producing the antibody.Type: GrantFiled: June 6, 1995Date of Patent: October 14, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 5618920Abstract: The invention relates to the secretion of heavy chain immunoglobulin fragments and light chain immunoglobulins from prokaryotic hosts using a prokaryotic secretion signal peptide wherein the heavy chain fragments and light chains are capable of associating to form an antigen binding antibody fragment.Type: GrantFiled: April 29, 1994Date of Patent: April 8, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5595898Abstract: The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human constant region modules and non-human variable region modules, or for class switching antibody molecules and/or chains.The invention also relates to DNA coding for pectate lyase signal peptide has been cloned on a plasmid to create a secretion vector which is capable of producing a chosen protein which is transported across the bacterial membrane. The secretion vector has been used to secrete extracellular thaumatin and extracellular chimeric antibody fragments. The proteins produced by this vector have biological activity. The thaumatin is properly folded and the antibody fragments are capable-of binding antigens on target cancer cells.Type: GrantFiled: August 18, 1994Date of Patent: January 21, 1997Assignee: Xoma CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Arnold H. Horwitz, Marc Better, Randolph Wall, Shau-Ping Lei, Gary L. Wilcox
-
Patent number: 5500362Abstract: The present invention relates to a chimeric IgG1 antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a human constant region and a variable region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. The invention also relates to the increased ADCC and CDC cytolytic activities of the chimeric antibody, methods of production by recombinant DNA techniques, and uses.Type: GrantFiled: March 5, 1991Date of Patent: March 19, 1996Assignee: XOMA CorporationInventors: Randy R. Robinson, Alvin Y. Liu, Jeffrey A. Ledbetter
-
Patent number: 5354847Abstract: A chimeric antibody with human constant region and murine variable region, having specificity to a human tumor antigen, methods of production, and uses. In particular, the present invention relates to a chimeric antibody specific for a human tumor antigen L6 and which mediates a potent antibody dependent cellular cytotoxicity against the tumor target cells.Type: GrantFiled: September 12, 1991Date of Patent: October 11, 1994Assignee: Bristol-Myers Squibb CompanyInventors: Alvin Y. Liu, Randy R. Robinson, Karl E. Hellstrom, Ingegred Hellstrom